Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib vs Chemotherapy in Advanced Endometrial Carcinoma
NCT04865289Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in endometrial carcinoma, sponsored by Merck & Co.. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT04865289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865289.